EFTA01980272

To: george church[ From: jeffrey E. Sent Mon 8/11/2014 1:28:31 PM Subject: Re: value decide what you would like to call your investment co. On Mon, Aug 11, 2014 at 7:27 AM, george church wrote: OK. Great. contact check with eGenesisBio.com and "Next generation pathology" teams and see who is most ready to take this on. What is the next step after that? --George From: "jeffrey E." <[email protected]> Date: Monday, August 11, 2014 at 9:04 AM To: george church Subject: Re: value lets start on first investment Below is a first pass list of potential investments for the $10M. This may be more information than you wanted at this point (especially given the trade-off between jargon and brevity), but I'm having so much fun, I just wanted to share it. I'm also recording a few extra thoughts, in case they provide "teaching moment" or post-mortem at some point. $200,000 $1,500,000 $1,000,000 $1,000,000 $1,000,000 $800,000 $1,550,000 $250,000 $200,000 $2,500,000 Supercentenarianstudv.com eGenesisEtio,com Sensor-$electors Protein stability & virus resistance Pest control Aging reversal Next generation pathology Space Genetics Cold-resistant elephants 2nd tranche $10,000,000 Total I ) Supercentenarianstudv.com Thirty genomes collected so far on a small budget by James Clement. $200K would get 8% ownership of the company and allow another 30 genomes to be collected, sequenced and therapies patented. 2) eGenesisBio.com: Using CRISPR to engineer animals for resistance to infectious diseases and to act as transplantation donors for major organs (initially kidneys) to humans. Co-founded with Prashant Mali and EFTA_R1_00488322 EFTA01980272 Luhan Yang. Already has a couple of contracts and a some rented lab space. 3) Sensor-selector technology for optimizing commercial production of (bio)chemicals. Lead by Vatsan Raman. 4) New redox-insensitive protein cross linking based on radically recoded bacterial genomes and/or Multi-virus- resistant organisms. We just published papers and patents on this. Lead by Dan Mandell. 5) Eliminating ecosystem pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR and other epigenetic reprogramming factors. Lead by Bobby Dhadwar and Eswar lyer. Possibly mergeable with Sunercentenarianstudy.com 7) A new sequencing method capable of displacing pan of the medical pathology imaging market and filling in the large gaps in most plant and animal genome sequences. Lead by Rich Terry. 8) Genome engineering of humans for space. Seed money for patent fees, some lab tests and education efforts via pgEd. Lead by Ting Wu. 9) Making cold-resistant elephants via CRISPR, focusing on blood, subcutaneous fat and wool/hair (based on what is know about cold-resistant animals, Mammoth DNA, and human mutations). Economics could be like the American Bison which recently grew from a hundred to 500,000 as a source of low cholesterol meat. Lead by Margo Monroe and Justin Quinn. Possibly mergeable with EgenesisBio. 10) The rest would be set aside as a second tranche for whichever of the above efforts makes best progress first. --George From: "Jeffrey E." <jeevacation@gmail com> Date: Thursday, July 10, 2014 at 8:07 AM To: george church Subject: Re: value I have a great idea. lets speak today if possible please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by c-mail to jscvacationftmail.com, and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA_R1_00488323 EFTA01980273 please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of WE Unauthorized use, disclosure or copying of this communication or any pan thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return c-mail or by e-mail to jccvacation®gmail.com, and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA_R1_004613324 EFTA01980274